This brand name is authorized in South Africa
The drug GRENDIS contains one active pharmaceutical ingredient (API):
|
1
Triflusal
UNII 1Z0YFI05OO - TRIFLUSAL
|
|
Triflusal reduces thromboxan biosynthesis through irreversible inhibition of platelet cyclooxygenase, sparing prostacyclin biosynthesis because its effect on vascular cyclooxygenase at therapeutic doses is negligible. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| B01AC18 | Triflusal | B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ZA | Health Products Regulatory Authority | Identifier(s): 44/8.2/0856 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
